These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28410220)
1. Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling. Chen XY; Li DF; Han JC; Wang B; Dong ZP; Yu LN; Pan ZH; Qu CJ; Chen Y; Sun SG; Zheng QS Oncotarget; 2017 May; 8(21):34565-34575. PubMed ID: 28410220 [TBL] [Abstract][Full Text] [Related]
2. Autophagy participates in isoliquiritigenin-induced melanin degradation in human epidermal keratinocytes through PI3K/AKT/mTOR signaling. Yang Z; Zeng B; Pan Y; Huang P; Wang C Biomed Pharmacother; 2018 Jan; 97():248-254. PubMed ID: 29091873 [TBL] [Abstract][Full Text] [Related]
3. Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway. Chen J; Liu C; Yang QQ; Ma RB; Ke Y; Dong F; Wu XE Chemotherapy; 2018; 63(3):155-161. PubMed ID: 29936511 [TBL] [Abstract][Full Text] [Related]
4. Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway. Zhang XR; Wang SY; Sun W; Wei C Mol Med Rep; 2018 Sep; 18(3):3429-3436. PubMed ID: 30066879 [TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of Isoliquiritigenin on the proliferation of human arterial smooth muscle cell. Chen T; Deng S; Lin R BMC Pharmacol Toxicol; 2017 Jul; 18(1):57. PubMed ID: 28716056 [TBL] [Abstract][Full Text] [Related]
7. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway. Huang Y; Liu C; Zeng WC; Xu GY; Wu JM; Li ZW; Huang XY; Lin RJ; Shi X Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840737 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1. Wang C; Chen Y; Wang Y; Liu X; Liu Y; Li Y; Chen H; Fan C; Wu D; Yang J J Exp Clin Cancer Res; 2019 Aug; 38(1):371. PubMed ID: 31438982 [TBL] [Abstract][Full Text] [Related]
9. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. Kwon GT; Cho HJ; Chung WY; Park KK; Moon A; Park JH J Nutr Biochem; 2009 Sep; 20(9):663-76. PubMed ID: 18824345 [TBL] [Abstract][Full Text] [Related]
10. Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling. Xiang S; Chen H; Luo X; An B; Wu W; Cao S; Ruan S; Wang Z; Weng L; Zhu H; Liu Q J Exp Clin Cancer Res; 2018 Aug; 37(1):184. PubMed ID: 30081934 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion. Zheng H; Li Y; Wang Y; Zhao H; Zhang J; Chai H; Tang T; Yue J; Guo AM; Yang J Toxicol Appl Pharmacol; 2014 Oct; 280(1):10-20. PubMed ID: 25094029 [TBL] [Abstract][Full Text] [Related]
12. LW-213 induces G2/M cell cycle arrest through AKT/GSK3β/β-catenin signaling pathway in human breast cancer cells. Zhao L; Miao HC; Li WJ; Sun Y; Huang SL; Li ZY; Guo QL Mol Carcinog; 2016 May; 55(5):778-92. PubMed ID: 25945460 [TBL] [Abstract][Full Text] [Related]
13. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation. Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309 [TBL] [Abstract][Full Text] [Related]
14. Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells. Wang Y; Ma J; Yan X; Chen X; Si L; Liu Y; Han J; Hao W; Zheng Q Recent Pat Anticancer Drug Discov; 2016; 11(2):215-27. PubMed ID: 26951491 [TBL] [Abstract][Full Text] [Related]
15. Isoliquiritigenin impairs insulin signaling and adipocyte differentiation through the inhibition of protein-tyrosine phosphatase 1B oxidation in 3T3-L1 preadipocytes. Park SJ; Choe YG; Kim JH; Chang KT; Lee HS; Lee DS Food Chem Toxicol; 2016 Jul; 93():5-12. PubMed ID: 27117918 [TBL] [Abstract][Full Text] [Related]
16. Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells. Li C; Zhou X; Sun C; Liu X; Shi X; Wu S Oncol Rep; 2019 Apr; 41(4):2502-2510. PubMed ID: 30720124 [TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt promotes feedforward mTORC2 activation through IKKα. Dan HC; Antonia RJ; Baldwin AS Oncotarget; 2016 Apr; 7(16):21064-75. PubMed ID: 27027448 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel isoliquiritigenin analogue ISL-17 as a potential anti-gastric cancer agent. Huang F; Wang J; Xu Y; Zhang Y; Xu N; Yin L Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32515470 [TBL] [Abstract][Full Text] [Related]
19. Isoliquiritigenin Induces Mitochondrial Dysfunction and Apoptosis by Inhibiting mitoNEET in a Reactive Oxygen Species-Dependent Manner in A375 Human Melanoma Cells. Chen XY; Ren HH; Wang D; Chen Y; Qu CJ; Pan ZH; Liu XN; Hao WJ; Xu WJ; Wang KJ; Li DF; Zheng QS Oxid Med Cell Longev; 2019; 2019():9817576. PubMed ID: 30805086 [TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative and cytotoxic activities of the flavonoid isoliquiritigenin in the human neuroblastoma cell line SH-SY5Y. Escobar SJM; Fong GM; Winnischofer SMB; Simone M; Munoz L; Dennis JM; Rocha MEM; Witting PK Chem Biol Interact; 2019 Feb; 299():77-87. PubMed ID: 30502331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]